DMRA Damora Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why DMRA matters now
Damora Therapeutics, Inc. (DMRA) is a US stock in Healthcare. The latest InvestLog snapshot shows $28.53 with -7.31% on the session and $1.76B in market capitalization; recent performance reads 1-month -11.69% and YTD -7.74%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-27.8M, and EPS of $-20.94. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.5%.
The latest indexable market news headline is "Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $40.00; recent insider activity includes Burkavage Brian filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.06
P/S
0.00
EV/EBITDA
-3.30
DCF Value
$194.39
FCF Yield
-1.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-122.6%
ROA
-43.9%
ROIC
-46.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-27.8M | $-20.94 |
| Q4 2025 | $0.00 | $-200.7M | $-151.27 |
| FY 2025 | $0.00 | $-209.8M | $-158.13 |
| Q3 2025 | $0.00 | $-3.1M | $-2.36 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$40.00
Target (Median)
$40.00
Target Range
$35.00 - $45.00
Trading Activity
Insider Trades
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.48
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.